Articles
In this study, researchers explored whether there is a potential synergistic effect of olaparib when combined with pegylated liposomal doxorubicin, highlighting a potential means to improve tolerability.
When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients.
Results from a previous study indicated that treatment with the combination would lead to improvement in progression-free survival (PFS) compared with treatment with olaparib alone.
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease.
Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer.
Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant.
In a systematic literature review that extracted data from 50 qualifying clinical trials, PARP inhibitor first-line maintenance improved progression-free survival (PFS) “across the board” versus other maintenance treatments in women with advanced ovarian cancer.
In a single-arm, single-institution study, combining pembrolizumab, bevacizumab, and metronomic oral cyclophosphamide led to a median progression-free survival of 10 months in women with recurrent ovarian cancer, with better response in women with platinum-sensitive disease.
An online educational tool about PARP inhibitors improved clinicians’ confidence in their ability to use them correctly in women with newly diagnosed advanced ovarian cancer.
Simulation-modeling data demonstrate significant cost-savings by converting from reference pegfilgrastim with on-body injector to biosimilar pegfilgrastim-jmdb for prophylaxis of chemotherapy-induced neutropenia/febrile neutropenia in patients with diffuse large B-cell lymphoma (DLBCL).